B. Power

发表

Lab-on-a-chip in vitro compartmentalization technologies for protein studies.

Yonggang Zhu, B. Power, Yonggang Zhu, 2008, Advances in biochemical engineering/biotechnology.

A new generation of protein display scaffolds for molecular recognition

B. Power, R. Hosse, A. Rothe, 2006, Protein science : a publication of the Protein Society.

DNA hypomethylation and human diseases.

P. Molloy, B. Power, Ann Wilson, 2007, Biochimica et biophysica acta.

Noncovalent scFv multimers of tumor‐targeting anti‐Lewisy hu3S193 humanized antibody

A. Scott, Zhanqi Liu, A. Kortt, 2003, Protein science : a publication of the Protein Society.

Novel proteins in emulsions using in vitro compartmentalization.

B. Power, A. Rothe, R. Surjadi, 2006, Trends in biotechnology.

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

A. Scott, J. Trapani, M. Smyth, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.

A. Scott, M. Brechbiel, P. Hudson, 2008, Cancer biotherapy & radiopharmaceuticals.

Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging.

P. Hudson, B. Power, 2000, Journal of immunological methods.

Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma

B. Power, P. Borchmann, A. Rothe, 2011, Molecular Cancer Therapeutics.

Synthesis of a specific oligodeoxyribonucleotide probe and its use for studying proenkephalin A gene expression

P. Hudson, B. Power, D. Scanlon, 1987, Neuroscience Letters.

Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.

A. Scott, M. Brechbiel, L. Old, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapeutic advances in rheumatology with the use of recombinant proteins

P. Hudson, B. Power, A. Rothe, 2008, Nature Clinical Practice Rheumatology.

Characterisation of an avian influenza virus nucleoprotein expressed inE. coli and in insect cells

P. Hudson, J. McKimm-Breschkin, B. Power, 1990, Archives of Virology.

Genomic structure of tbe large RNA segment of infectious bursal disease virus

A. Azad, P. Hudson, N. Mckern, 1986 .

High-level temperature-induced synthesis of an antibody VH-domain in Escherichia coli using the PelB secretion signal.

R. Webster, A. Kortt, P. Hudson, 1992, Gene.

Ribosome display and selection of human anti-CD22 scFvs derived from an acute lymphocytic leukemia patient

P. Hudson, B. Power, A. Rothe, 2008, Biological chemistry.

Generation of recombinant multimeric antibody fragments for tumor diagnosis and therapy.

A. Kortt, P. Hudson, B. Power, 2003, Methods in molecular biology.

Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display.

P. Hudson, B. Power, R. Hosse, 2007, Journal of biotechnology.

The Anti-Cancer IgM Monoclonal Antibody PAT-SM6 Binds with High Avidity to the Unfolded Protein Response Regulator GRP78

T. Mulhern, G. Howlett, L. Ilag, 2012, PloS one.

The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.

A. Wu, P. Hudson, J. Shively, 2003, Journal of molecular biology.

Genomic structure of the large RNA segment of infectious bursal disease virus.

A. Azad, P. Hudson, N. Mckern, 1986, Nucleic acids research.

Retinoic acid and tumour necrosis factor-alpha act in concert to control the level of alkaline phosphatase mRNA.

T. Martin, P. Hudson, B. Power, 1989, Journal of molecular endocrinology.

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector

Andrew M. Scott, Alexander A. Kortt, Barbara E. Power, 2001, Cancer Immunology, Immunotherapy.

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

A. Kortt, P. Hudson, O. Dolezal, 2001, Biomolecular engineering.

Infectivity and virulence of Australian strains of Moraxella bovis for the murine and bovine eye in relation to pilus serogroup sub-unit size and degree of piliation.

B. Power, A. Lepper, 1988, Australian veterinary journal.

Recombinant antineuraminidase single chain antibody: Expression, characterization, and crystallization in complex with antigen

R. Webster, P. Colman, A. Kortt, 1993, Proteins.

Ribosome display for improved biotherapeutic molecules

B. Power, R. Hosse, A. Rothe, 2006, Expert opinion on biological therapy.

Large-scale bacterial fermentation and isolation of scFv multimers using a heat-inducible bacterial expression vector.

A. Kortt, P. Hudson, B. Power, 2002, Journal of immunological methods.

Solution properties ofEscherichia coli-expressed VH domain of anti-neuraminidase antibody NC41

R. Norton, M. Hinds, A. Kortt, 1995, Journal of protein chemistry.

Selection of human anti-CD22 scFvs from an acute lymphocytic leukemia related scFv library with ribosome display.

P. Hudson, B. Power, R. Hosse, 2006 .

Keystone Symposia: Antibody-based therapeutics for cancer

P. Hudson, B. Power, 2003, Expert opinion on biological therapy.

High-level temperature-induced synthesis of an antibody VH-domain in Escherichia coli using the PeiB secretion signal (Recombinant DNA; PCR; tandem phage 2 promoters; neuraminidase; variable domains; FLAG peptide tail)

R. Webster, A. Kortt, B. Power, 1992 .

Lab-on-a-chip in vitro compartmentalization technologies for protein studies.

Yonggang Zhu, B. Power, 2008, Advances in biochemical engineering/biotechnology.